Nutrition & Care
Q3 2022
The Nutrition & Care segment increased sales considerably compared with the prior-year quarter. Both divisions achieved strong sales growth.
|
Nutrition & Care |
Care Chemicals |
Nutrition & Health |
|---|---|---|---|
Volumes |
–1.1% |
–2.6% |
2.1% |
Prices |
27.5% |
33.6% |
13.8% |
Portfolio |
–0.2% |
–0.2% |
–0.2% |
Currencies |
6.7% |
6.1% |
7.9% |
Sales |
32.8% |
36.9% |
23.6% |
Sales performance was driven by significant price increases in all business areas as a result of higher energy and raw materials prices.
Currency effects, mainly from the U.S. dollar and the Chinese renminbi, also had a positive impact on sales.
Sales were dampened by slightly lower volumes overall. The Care Chemicals division recorded a decline in volumes, particularly in the oleo surfactants and alcohols business and in the home care, industrial and institutional cleaning and industrial formulators business. Higher volumes in the personal care solutions business were unable to compensate for this. Slight volume growth in the Nutrition & Health division was mainly driven by higher sales volumes in the animal nutrition business.
The segment posted a considerable increase in income from operations (EBIT) before special items. This was due to strong earnings growth in the Care Chemicals division. The division recorded higher margins, mainly driven by sales growth. By contrast, EBIT before special items declined considerably in the Nutrition & Health division. This was mainly attributable to higher fixed costs resulting from turnarounds and higher prices for energy and raw materials.
|
Q3 |
January–September |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2022 |
2021 |
+/– |
2022 |
2021 |
+/– |
||||||||||||
Sales to third parties |
2,123 |
1,598 |
32.8% |
6,167 |
4,715 |
30.8% |
||||||||||||
of which Care Chemicals |
1,517 |
1,108 |
36.9% |
4,341 |
3,250 |
33.6% |
||||||||||||
Nutrition & Health |
605 |
490 |
23.6% |
1,827 |
1,465 |
24.7% |
||||||||||||
Income from operations before depreciation, amortization and special items |
291 |
206 |
41.3% |
967 |
761 |
27.1% |
||||||||||||
Income from operations before depreciation and amortization (EBITDA) |
287 |
207 |
38.9% |
963 |
815 |
18.2% |
||||||||||||
Depreciation and amortizationa |
110 |
102 |
7.6% |
330 |
301 |
9.6% |
||||||||||||
Income from operations (EBIT) |
178 |
105 |
69.3% |
633 |
514 |
23.1% |
||||||||||||
Special items |
–3 |
1 |
. |
–4 |
54 |
. |
||||||||||||
EBIT before special items |
180 |
104 |
73.3% |
637 |
460 |
38.6% |
||||||||||||
Assets (September 30) |
8,460 |
6,911 |
22.4% |
8,460 |
6,911 |
22.4% |
||||||||||||
Investments including acquisitionsb |
161 |
196 |
–17.8% |
404 |
414 |
–2.5% |
||||||||||||
Research and development expenses |
39 |
39 |
0.5% |
124 |
122 |
1.7% |
||||||||||||
|
||||||||||||||||||